Scientists are hopeful that ultimately these cells could be transformed in the laboratory to yield specific cell types needed for a particular treatment, or to cross the «blood - brain barrier» by expressing
specific therapeutic agents that are released directly into the brain.
Not exact matches
Most industry experts agree that personalized medicine and theranostics — diagnostic tests bundled with
therapeutic agents to treat a
specific disease — point to a bright future for the industry.
The study, called «Molecular Determinants of Drug -
Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of
therapeutic agents to treat patients.
Researchers are focused primarily on three ways to make a
therapeutic agent out of CRISPR, in which a guide RNA directs the Cas9 enzyme to a
specific location in DNA for precise editing.
Our group has 3 major goals: Develop novel
therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and
specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel
agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma